Grosso Federica, Mannucci Matilde, Ugo Francesca, Ferro Paola, Cassinari Maurizio, Vigani Antonella, De Angelis Antonina Maria, Delfanti Sara, Lia Michela, Guaschino Roberto, Barbero Stefano, Roncella Silvio, Giannoni Ugo, Bertolotti Marinella, Pistillo Maria Pia, Fontana Vincenzo
Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy.
Translational Medicine, Dipartimento Attività Integrate Ricerca e Innovazione, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy.
Diagnostics (Basel). 2021 Oct 29;11(11):2015. doi: 10.3390/diagnostics11112015.
A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker for diagnosis of pleural mesothelioma (PM) and the most used for monitoring treatment. Radiological assessment of PM, based on modified RECIST (mRECIST) criteria, is challenging. This pilot study was designed to evaluate whether SMRP levels correlated over time with mRECIST score. Serial serum samples from PM patients were collected and SMRP levels were measured and compared with the mRECIST score obtained through centralized CT scans by blinded review. The within-patient SMRP-mRECIST relationship over time was estimated through a normal random-effects regression approach applied to the log-transformed mRECIST score. Overall, 58 PM patients were included (46 males and 12 females) with a median age at diagnosis of 67 years (min-max = 48-79), 44 (76%) with epithelioid and 14 (24%) with non-epithelioid histology. The total number of SMRP measurements and CT scans considered for analysis was 183. There was a statistically significant correlation between SMRP and mRECIST score in the 2 cohorts considered both separately and jointly. These results, although exploratory, suggest that SMRP measurement might be considered as an adjunct to monitor PM patients in order to delay CT scans time interval, thus warranting further investigation.
可溶性间皮素相关肽（SMRP）是美国食品药品监督管理局（FDA）批准的唯一用于诊断胸膜间皮瘤（PM）的生物标志物，也是最常用于监测治疗的标志物。基于改良RECIST（mRECIST）标准对PM进行放射学评估具有挑战性。本初步研究旨在评估SMRP水平随时间推移是否与mRECIST评分相关。收集了PM患者的系列血清样本，测量了SMRP水平，并与通过盲法回顾集中式CT扫描获得的mRECIST评分进行比较。通过应用于对数转换后的mRECIST评分的正态随机效应回归方法，估计了患者体内SMRP与mRECIST随时间的关系。总体而言，纳入了58例PM患者（46例男性和12例女性），诊断时的中位年龄为67岁（最小-最大=48-79岁），44例（76%）为上皮样组织学类型，14例（24%）为非上皮样组织学类型。用于分析的SMRP测量和CT扫描总数为183次。在单独和联合考虑的两个队列中，SMRP与mRECIST评分之间均存在统计学显著相关性。这些结果虽然是探索性的，但表明SMRP测量可被视为监测PM患者的辅助手段，以延长CT扫描的时间间隔，因此值得进一步研究。
